Cargando…

Development of novel parameter for monitoring of malignant melanoma progression

OBJECTIVE: Increasing HIFs in malignant melanoma, the highly aggressive skin tumour, results in the stimulation of invasiveness. Increased HIF-1α fallouts in inhibition of the activity of some mitochondrial enzymes and leads to preference of cytosol energetic metabolism. Increase of aerobic glycolys...

Descripción completa

Detalles Bibliográficos
Autores principales: Špaková, Ivana, Rabajdová, Miroslava, Dubayová, Katarína, Nagyová, Vladimíra, Pilátová, Martina Bago, Mareková, Mária
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586240/
https://www.ncbi.nlm.nih.gov/pubmed/33134468
http://dx.doi.org/10.1016/j.plabm.2020.e00182
_version_ 1783599955016941568
author Špaková, Ivana
Rabajdová, Miroslava
Dubayová, Katarína
Nagyová, Vladimíra
Pilátová, Martina Bago
Mareková, Mária
author_facet Špaková, Ivana
Rabajdová, Miroslava
Dubayová, Katarína
Nagyová, Vladimíra
Pilátová, Martina Bago
Mareková, Mária
author_sort Špaková, Ivana
collection PubMed
description OBJECTIVE: Increasing HIFs in malignant melanoma, the highly aggressive skin tumour, results in the stimulation of invasiveness. Increased HIF-1α fallouts in inhibition of the activity of some mitochondrial enzymes and leads to preference of cytosol energetic metabolism. Increase of aerobic glycolysis is reflected in an increase of free NADH (Warburg effect) and develops the malignant melanoma. Our goal was to find a link between hypoxia, or hypoxia mimicking factors and the stage of malignant melanoma. Furthermore, we focused on the finding of the experimental parameter which could monitor melanoma patients. PATIENTS AND METHODS: We targeted HIF-1α gene expression and VDR rs2107301 gene polymorphism by PCR analysis. We detected the level of NADH in blood plasma by fluorescence spectroscopy (excitation and emission spectra). RESULTS: Analysis of the obtained data from patient samples has shown an increase in HIF-1α which correlates with the disease stage. Investigation VDR rs2107301 polymorphism of patient samples does not show any significant changes in single nucleotide polymorphism, and the low vitamin D level in blood is not a result of VDR mutation in mitochondria. NADH levels vary under hypoxic and pseudohypoxic conditions and refer to the cancer stage. CONCLUSIONS: The apparent mismatch between HIF-1α expression and NADH fluorescence has become the basis for the design of an algorithm for monitoring malignant melanoma based on the sensing of NADH fluorescence and the determination of HIF-1α.
format Online
Article
Text
id pubmed-7586240
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-75862402020-10-30 Development of novel parameter for monitoring of malignant melanoma progression Špaková, Ivana Rabajdová, Miroslava Dubayová, Katarína Nagyová, Vladimíra Pilátová, Martina Bago Mareková, Mária Pract Lab Med Article OBJECTIVE: Increasing HIFs in malignant melanoma, the highly aggressive skin tumour, results in the stimulation of invasiveness. Increased HIF-1α fallouts in inhibition of the activity of some mitochondrial enzymes and leads to preference of cytosol energetic metabolism. Increase of aerobic glycolysis is reflected in an increase of free NADH (Warburg effect) and develops the malignant melanoma. Our goal was to find a link between hypoxia, or hypoxia mimicking factors and the stage of malignant melanoma. Furthermore, we focused on the finding of the experimental parameter which could monitor melanoma patients. PATIENTS AND METHODS: We targeted HIF-1α gene expression and VDR rs2107301 gene polymorphism by PCR analysis. We detected the level of NADH in blood plasma by fluorescence spectroscopy (excitation and emission spectra). RESULTS: Analysis of the obtained data from patient samples has shown an increase in HIF-1α which correlates with the disease stage. Investigation VDR rs2107301 polymorphism of patient samples does not show any significant changes in single nucleotide polymorphism, and the low vitamin D level in blood is not a result of VDR mutation in mitochondria. NADH levels vary under hypoxic and pseudohypoxic conditions and refer to the cancer stage. CONCLUSIONS: The apparent mismatch between HIF-1α expression and NADH fluorescence has become the basis for the design of an algorithm for monitoring malignant melanoma based on the sensing of NADH fluorescence and the determination of HIF-1α. Elsevier 2020-10-21 /pmc/articles/PMC7586240/ /pubmed/33134468 http://dx.doi.org/10.1016/j.plabm.2020.e00182 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Špaková, Ivana
Rabajdová, Miroslava
Dubayová, Katarína
Nagyová, Vladimíra
Pilátová, Martina Bago
Mareková, Mária
Development of novel parameter for monitoring of malignant melanoma progression
title Development of novel parameter for monitoring of malignant melanoma progression
title_full Development of novel parameter for monitoring of malignant melanoma progression
title_fullStr Development of novel parameter for monitoring of malignant melanoma progression
title_full_unstemmed Development of novel parameter for monitoring of malignant melanoma progression
title_short Development of novel parameter for monitoring of malignant melanoma progression
title_sort development of novel parameter for monitoring of malignant melanoma progression
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586240/
https://www.ncbi.nlm.nih.gov/pubmed/33134468
http://dx.doi.org/10.1016/j.plabm.2020.e00182
work_keys_str_mv AT spakovaivana developmentofnovelparameterformonitoringofmalignantmelanomaprogression
AT rabajdovamiroslava developmentofnovelparameterformonitoringofmalignantmelanomaprogression
AT dubayovakatarina developmentofnovelparameterformonitoringofmalignantmelanomaprogression
AT nagyovavladimira developmentofnovelparameterformonitoringofmalignantmelanomaprogression
AT pilatovamartinabago developmentofnovelparameterformonitoringofmalignantmelanomaprogression
AT marekovamaria developmentofnovelparameterformonitoringofmalignantmelanomaprogression